TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 29693757

Group type: EXPERIMENTAL
Intervention: Adjunctive probiotics (Lactobacillus rhamnosus strain GG and Bifidobacterium animalis subsp. lactis strain Bb12)
Number of subjects: 66

Group type: COMPARATOR
Intervention: Adjunctive placebo
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Adjunctive probiotics
Number of subjects: 66
Study: 27275617

Group type: EXPERIMENTAL
Intervention: Temporary Anchorage Devices (TADs) for canine disimpaction before bracket placement
Number of subjects: 34

Group type: COMPARATOR
Intervention: Cantilever spring soldered to a palatal bar for canine disimpaction after initiation of comprehensive orthodontics
Number of subjects: 34
Study: 25317545

Group type: EXPERIMENTAL
Intervention: Butorphanol 0.015 mg/kg
Number of subjects: 108

Group type: COMPARATOR
Intervention: Saline (Control)
Number of subjects: 108
Study: 22525902

Group type: EXPERIMENTAL
Intervention: Antenatal corticosteroids
Number of subjects: 2304
Study: 20353028

Group type: EXPERIMENTAL
Intervention: Liangxue Shengji Recipe (LSR)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Conventional Western treatment
Number of subjects: 100
Study: 17663737

Group type: EXPERIMENTAL
Intervention: YM150 3 mg
Number of subjects: 174

Group type: EXPERIMENTAL
Intervention: YM150 10 mg
Number of subjects: 174

Group type: EXPERIMENTAL
Intervention: YM150 30 mg
Number of subjects: 174

Group type: EXPERIMENTAL
Intervention: YM150 60 mg
Number of subjects: 174

Group type: COMPARATOR
Intervention: Enoxaparin (40 mg daily)
Number of subjects: 174
Study: 15591292

Group type: EXPERIMENTAL
Intervention: Exercise at 65% V(O2 peak)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Exercise at 45% V(O2 peak)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Con (no-exercise)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Postexercise recovery after 45% exercise
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Postexercise recovery after 65% exercise
Number of subjects: 12
Study: 12393314

Group type: EXPERIMENTAL
Intervention: Venlafaxine (immediate release and extended release)
Number of subjects: 2045

Group type: EXPERIMENTAL
Intervention: Selective serotonin reuptake inhibitors (SSRIs)
Number of subjects: 2045

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2045

Group type: EXPERIMENTAL
Intervention: Venlafaxine vs. SSRIs
Number of subjects: 2045

Group type: EXPERIMENTAL
Intervention: Final subscale scores
Number of subjects: 2045
Study: 9928755

Group type: EXPERIMENTAL
Intervention: Nifedipine GITS 20 mg once daily
Number of subjects: 200

Group type: COMPARATOR
Intervention: Bendrofluazide 2.5 mg once daily
Number of subjects: 200
Study: 7755188

Group type: EXPERIMENTAL
Intervention: Artery-ligated group
Number of subjects: 66

Group type: COMPARATOR
Intervention: Artery-preserved group
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 66
Study: 2373879

Group type: EXPERIMENTAL
Intervention: Antibiotic therapy
Number of subjects: 58

Group type: COMPARATOR
Intervention: Bacterial pathogens alone
Number of subjects: 58
Study: 6756418

Group type: EXPERIMENTAL
Intervention: Niludipine 20 mg, 4 times a day
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Niludipine 60 mg
Number of subjects: 28

Group type: COMPARATOR
Intervention: Niludipine 60 mg in normotensives
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Niludipine + Propranolol 10 mg, 4 times a day
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Niludipine + Propranolol + Penfluzide 2.5 mg a day
Number of subjects: 28
Study: 30570162

Group type: EXPERIMENTAL
Intervention: Bolus gastric feeding (B-GF)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Continuous gastric feeding (C-GF)
Number of subjects: 25
Study: 29977846

Group type: EXPERIMENTAL
Intervention: W incision
Number of subjects: 93

Group type: COMPARATOR
Intervention: Inverted-V incision
Number of subjects: 93
Study: 26499175

Group type: EXPERIMENTAL
Intervention: LEO 43204 0·025%
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: LEO 43204 0·05%
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: LEO 43204 0·075%
Number of subjects: 40

Group type: COMPARATOR
Intervention: ingenol mebutate 0·05%
Number of subjects: 40
Study: 24907420

Group type: EXPERIMENTAL
Intervention: Selective hepatic vascular exclusion (SHVE)
Number of subjects: 160

Group type: COMPARATOR
Intervention: Pringle manoeuvre
Number of subjects: 160
Study: 22662740

Group type: EXPERIMENTAL
Intervention: Telephone-delivered cognitive-behavioral therapy (CBT)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 0
Study: 19654139

Group type: COMPARATOR
Intervention: Bone-marrow-derived stem cells (BMSC) administered by intracoronary infusion
Number of subjects: 1091

Group type: EXPERIMENTAL
Intervention: Bone-marrow-derived stem cells (BMSC) delivered by intra-myocardial injection
Number of subjects: 1091

Group type: EXPERIMENTAL
Intervention: Bone-marrow-derived stem cells (BMSC) in chronic IHD patients with lower baseline LVEF
Number of subjects: 1091
Study: 17617290

Group type: EXPERIMENTAL
Intervention: Generic terazosin (2 mg/d for 2 weeks, then adjusted to 1 mg/d or 4 mg/d)
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: Branded terazosin (2 mg/d for 2 weeks, then adjusted to 1 mg/d or 4 mg/d)
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: Generic terazosin
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: Branded terazosin
Number of subjects: 53
Study: 14694168

Group type: EXPERIMENTAL
Intervention: Intravenous methylprednisolone plus oral prednisone
Number of subjects: 86

Group type: COMPARATOR
Intervention: Supportive therapy
Number of subjects: 86
Study: 11576413

Group type: EXPERIMENTAL
Intervention: 0.1% mometasone furoate ointment
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: 0.005% fluticasone proprionate ointment
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Wet wraps with either ointment after 2 weeks
Number of subjects: 40
Study: 9506330

Group type: EXPERIMENTAL
Intervention: Thrombolytic therapy
Number of subjects: 17944
Study: 8034522

Group type: EXPERIMENTAL
Intervention: Ceftriaxone (half-life 8 hours)
Number of subjects: 429

Group type: COMPARATOR
Intervention: Cefazolin (half-life 2 hours)
Number of subjects: 429

Group type: EXPERIMENTAL
Intervention: Ceftriaxone/Ornidazole (half-life 13 hours)
Number of subjects: 429

Group type: COMPARATOR
Intervention: Cefazolin/Metronidazole (half-life 8 hours)
Number of subjects: 429

Group type: EXPERIMENTAL
Intervention: Ornidazole
Number of subjects: 429

Group type: COMPARATOR
Intervention: Clindamycin
Number of subjects: 429

Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 429
Study: 2656860

Group type: EXPERIMENTAL
Intervention: Captopril 50 mg (11 patients) and 25 mg (1 patient) twice daily for 4 weeks
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Captopril
Number of subjects: 12
Study: 30946436

Group type: COMPARATOR
Intervention: Telerehabilitation arm (arm 2)
Number of subjects: 516

Group type: COMPARATOR
Intervention: Telerehabilitation with pharmacological pain management arm (arm 3)
Number of subjects: 516
Study: 28255731

Group type: EXPERIMENTAL
Intervention: Moderate exercise (60 min of treadmill walking) in a post-absorptive state
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Moderate exercise (60 min of treadmill walking) in a postprandial state
Number of subjects: 12

Group type: COMPARATOR
Intervention: Control condition (no exercise)
Number of subjects: 12
Study: 25483215

Group type: EXPERIMENTAL
Intervention: Rivaroxaban
Number of subjects: 2397

Group type: COMPARATOR
Intervention: Enoxaparin/VKA
Number of subjects: 2397
Study: 24055199

Group type: EXPERIMENTAL
Intervention: Visual perspective-taking task during functional magnetic resonance imaging
Number of subjects: 20
Study: 21498786

Group type: EXPERIMENTAL
Intervention: Glargine
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Detemir
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: NPH
Number of subjects: 18
Study: 19750263

Group type: EXPERIMENTAL
Intervention: Extra parenteral fluid therapy (group I)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Early nasal intermittent positive pressure ventilation (NIPPV)
Number of subjects: 100
Study: 16989902

Group type: EXPERIMENTAL
Intervention: Implantable telescope (IMT)
Number of subjects: 217

Group type: COMPARATOR
Intervention: Fellow eye controls
Number of subjects: 217
Study: 12974172

Group type: EXPERIMENTAL
Intervention: Hormone Replacement Therapy (HRT)
Number of subjects: 0
Study: 11126933

Group type: EXPERIMENTAL
Intervention: Normal text or RSVP text (coherent or scrambled)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Words presented in text
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Study list words presented in RSVP
Number of subjects: 0

Group type: COMPARATOR
Intervention: Words read aloud in a list
Number of subjects: 0
Study: 9307346

Group type: EXPERIMENTAL
Intervention: Intravenous ampicillin (2-g dose every 6 hours) and erythromycin (250-mg dose every 6 hours) for 48 hours followed by oral amoxicillin (250-mg dose every 8 hours) and erythromycin base (333-mg dose every 8 hours) for 5 days
Number of subjects: 614

Group type: COMPARATOR
Intervention: Matching placebo regimen
Number of subjects: 614

Group type: EXPERIMENTAL
Intervention: Intravenous ampicillin and erythromycin
Number of subjects: 614

Group type: COMPARATOR
Intervention: Matching placebo regimen in GBS-negative cohort
Number of subjects: 614
Study: 8103875

Group type: EXPERIMENTAL
Intervention: Intravenous streptokinase (SK) 1.5 MU
Number of subjects: 4534

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 4534
Study: 3734034

Group type: COMPARATOR
Intervention: RU 486 (400 mg acute administration)
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: RU 486 (400 mg daily for 3 days)
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: RU 486 (in two patients with nonpituitary-dependent Cushing's syndrome)
Number of subjects: 7
Study: 31667859

Group type: EXPERIMENTAL
Intervention: Organizational skills intervention / Homework completion intervention
Number of subjects: 274
Study: 28695791

Group type: EXPERIMENTAL
Intervention: L+Z supplementation (12 mg/daily)
Number of subjects: 44

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 44
Study: 27775995

Group type: EXPERIMENTAL
Intervention: Intraoperative alerts for double-low events
Number of subjects: 19292

Group type: COMPARATOR
Intervention: No alerts (Control)
Number of subjects: 19292

Group type: EXPERIMENTAL
Intervention: Cumulative double-low time > 60 min
Number of subjects: 19292

Group type: EXPERIMENTAL
Intervention: Median number of double-low minutes
Number of subjects: 19292
Study: 24635053

Group type: EXPERIMENTAL
Intervention: 3-ounce water swallowing test
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: Swallowing function questionnaire
Number of subjects: 47
Study: 22507791

Group type: EXPERIMENTAL
Intervention: R-CHOP (rituximab, cyclophosphamide, adriamycin, vincristine, and prednisone)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: R-ACVBP
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Autologous stem cell transplantation (ASCT)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: R-ICE or R-DHAP followed by different conditioning regimens prior to ASCT
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: New agents targeting different pathways such as lenalidomide
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: New monoclonal antibodies
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Bruton’s tyrosine kinase inhibitor
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Targeted therapy
Number of subjects: 0
Study: 20702739

Group type: EXPERIMENTAL
Intervention: Opponent-channel model response to outward ITD change
Number of subjects: 0

Group type: COMPARATOR
Intervention: Topographic model response to inward ITD change
Number of subjects: 0
Study: 18700639

Group type: EXPERIMENTAL
Intervention: Self care manual educational intervention
Number of subjects: 523

Group type: COMPARATOR
Intervention: Control group (no access to self care manual)
Number of subjects: 523
Study: 15967223

Group type: EXPERIMENTAL
Intervention: Cerebrospinal fluid (CSF) levels of endothelin-1 (ET-1) in patients with SAH
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Cerebrospinal fluid (CSF) levels of ET-1 in patients with different groups of the Hunt-Hess scale
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Plasma levels of ET-1 in patients with SAH
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control group (healthy volunteers)
Number of subjects: 30
Study: 12809395

Group type: EXPERIMENTAL
Intervention: Chest tubes removed as soon as the drainage fluid turned to serosanguineous.
Number of subjects: 80

Group type: COMPARATOR
Intervention: Chest tubes removed at the second postoperative day when drainage output declined to less than 50 mL in a five-hour period.
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Drain hematocrit to blood hematocrit ratio before drain removal.
Number of subjects: 80
Study: 10574299

Group type: EXPERIMENTAL
Intervention: Alcohol-specific support
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: General social support
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Both general and alcohol-specific support
Number of subjects: 0
Study: 8919517

Group type: EXPERIMENTAL
Intervention: Baby wipes with pH 2.8
Number of subjects: 302

Group type: EXPERIMENTAL
Intervention: Baby wipes with pH 5.5
Number of subjects: 302

Group type: EXPERIMENTAL
Intervention: Baby wipes with intermediate pH 3.7
Number of subjects: 302

Group type: COMPARATOR
Intervention: Soap and water (control)
Number of subjects: 302
Study: 1365219

Group type: EXPERIMENTAL
Intervention: Cognitive information (rational and accurate explanation)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Watching a monitor (regardless of content)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Accurate monitoring of hand temperature
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Motivation and self-efficacy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Self prediction of anticipated performance
Number of subjects: 0
Study: 7038244

Group type: EXPERIMENTAL
Intervention: Xeromammogram interpretation by radiologists
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Diagnosis of cancer
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Diagnosis of benign abnormalities
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Diagnosis of normality
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Known cancers identification
Number of subjects: 100
Study: 31907007

Group type: EXPERIMENTAL
Intervention: Therapeutic drug monitoring (TDM) of infliximab
Number of subjects: 850

Group type: COMPARATOR
Intervention: Standard treatment with infliximab without knowledge of drug levels or ADAb status
Number of subjects: 850
Study: 31432589

Group type: EXPERIMENTAL
Intervention: Lateral indentation angle
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Lateral indentation depth
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: T-angle
Number of subjects: 100
Study: 28745674

Group type: EXPERIMENTAL
Intervention: CCM gene mutations (CCM1, CCM2, CCM3) identified through blood sample analysis and whole genome sequencing.
Number of subjects: 73

Group type: EXPERIMENTAL
Intervention: CCM3 mutations
Number of subjects: 73

Group type: EXPERIMENTAL
Intervention: Patients with mutations
Number of subjects: 73

Group type: EXPERIMENTAL
Intervention: Familial CCMs
Number of subjects: 73
Study: 25982006

Group type: EXPERIMENTAL
Intervention: CBT4CBT
Number of subjects: 73

Group type: COMPARATOR
Intervention: Treatment as usual
Number of subjects: 73
Study: 23770919

Group type: EXPERIMENTAL
Intervention: Intramuscular injection with 400 μg cobalamin
Number of subjects: 107

Group type: COMPARATOR
Intervention: No intervention
Number of subjects: 107
Study: 21386706

Group type: EXPERIMENTAL
Intervention: Intensive treatment with amlodipine/valsartan (10/320 mg)
Number of subjects: 728

Group type: EXPERIMENTAL
Intervention: Moderate treatment with amlodipine/valsartan (5/160 mg)
Number of subjects: 728

Group type: EXPERIMENTAL
Intervention: Intensive treatment
Number of subjects: 728

Group type: COMPARATOR
Intervention: Moderate treatment
Number of subjects: 728
Study: 19393782

Group type: EXPERIMENTAL
Intervention: Sensation seeking
Number of subjects: 1587

Group type: EXPERIMENTAL
Intervention: Heavy episodic drinking, living off-campus, going to bars
Number of subjects: 1587
Study: 17921831

Group type: EXPERIMENTAL
Intervention: Spironolactone (12.5-50 mg/day for 3 months)
Number of subjects: 98

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 98
Study: 15156996

Group type: EXPERIMENTAL
Intervention: IN‐BP (intranasal vaccine without canine‐adenovirus type 2)
Number of subjects: 972

Group type: EXPERIMENTAL
Intervention: IN‐BPA (intranasal vaccine with canine‐adenovirus type 2)
Number of subjects: 972

Group type: COMPARATOR
Intervention: Placebo vaccine
Number of subjects: 972

Group type: EXPERIMENTAL
Intervention: IN‐BP
Number of subjects: 972

Group type: EXPERIMENTAL
Intervention: IN‐BPA
Number of subjects: 972

Group type: EXPERIMENTAL
Intervention: All vaccine groups
Number of subjects: 972

Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 972
Study: 12490862

Group type: EXPERIMENTAL
Intervention: OC 3 g per day
Number of subjects: 79

Group type: EXPERIMENTAL
Intervention: OC 3 g + VD 1 mg per day
Number of subjects: 79

Group type: COMPARATOR
Intervention: No treatment (group A)
Number of subjects: 79
Study: 10321142

Group type: EXPERIMENTAL
Intervention: Extraction
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Non-extraction
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Orthodontics
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Surgery
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Fixed treatments
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Functional treatments
Number of subjects: 0
Study: 7840077

Group type: EXPERIMENTAL
Intervention: Very-low-energy diets (VLEDs)
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Oral-glucose-tolerance test (OGTT) on day 14
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Oral-sucrose-tolerance test (OSTT) on day 14
Number of subjects: 13
Study: 2239174

Group type: EXPERIMENTAL
Intervention: Cefotaxime (Claforan)
Number of subjects: 38

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 38
Study: 20656

Group type: EXPERIMENTAL
Intervention: Benorylate tablets (4.5 g daily dosage)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 30115499

Group type: EXPERIMENTAL
Intervention: Ketamine
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study: 28355317

Group type: EXPERIMENTAL
Intervention: Classical music 'Spring' from The Four Seasons by Vivaldi
Number of subjects: 40
Study: 26193987

Group type: EXPERIMENTAL
Intervention: Gravity-fed infusion (GFI)
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Infusion pump (IP)
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Gravity-fed infusion with post-administration rinsing (PAR)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Control group (GFI and IP)
Number of subjects: 25
Study: 23914761

Group type: EXPERIMENTAL
Intervention: Fearful face presentation
Number of subjects: 0

Group type: COMPARATOR
Intervention: Neutral face presentation
Number of subjects: 0
Study: 21862934

Group type: EXPERIMENTAL
Intervention: Combination therapy of plasmapheresis and immunosuppression
Number of subjects: 221

Group type: EXPERIMENTAL
Intervention: Steroids and cytotoxic agents
Number of subjects: 221

Group type: EXPERIMENTAL
Intervention: Steroids alone
Number of subjects: 221

Group type: EXPERIMENTAL
Intervention: Combination therapy of plasmapheresis plus corticosteroids and cyclophosphamide
Number of subjects: 221

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 221
Study: 19251134

Group type: EXPERIMENTAL
Intervention: Wavefront-guided LASIK with iris registration (LASIK+IR group)
Number of subjects: 3

Group type: COMPARATOR
Intervention: Conventional LASIK and manual marking
Number of subjects: 3

Group type: COMPARATOR
Intervention: Wavefront-guided LASIK and manual marking
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: LASIK+IR group
Number of subjects: 3
Study: 17320090

Group type: EXPERIMENTAL
Intervention: Chokeberry flavonoid extract (3 x 85 mg/day)
Number of subjects: 44

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 44
Study: 15025841

Group type: EXPERIMENTAL
Intervention: Ximelagatran swallowed whole
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Ximelagatran crushed and mixed with applesauce
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Ximelagatran dissolved in water and administered via nasogastric tube
Number of subjects: 40
Study: 12575392

Group type: EXPERIMENTAL
Intervention: Recombinant roasted licorice decoction (RRLD) plus low-dose glucocorticoids (GC)
Number of subjects: 43

Group type: COMPARATOR
Intervention: Normal dosage of glucocorticoids (GC)
Number of subjects: 43
Study: 9490238

Group type: EXPERIMENTAL
Intervention: Non-Q-wave infarction
Number of subjects: 2046
Study: 7874375

Group type: EXPERIMENTAL
Intervention: benazepril 5 mg + hydrochlorothiazide 6.25 mg
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: benazepril 10 mg + hydrochlorothiazide 12.5 mg
Number of subjects: 18

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 18
Study: 3044673

Group type: EXPERIMENTAL
Intervention: Hexopal (4 g/day)
Number of subjects: 23

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 23
Study: 31944491

Group type: COMPARATOR
Intervention: Heparin
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: Argatroban
Number of subjects: 84
Study: 31675993

Group type: EXPERIMENTAL
Intervention: Tamoxifen
Number of subjects: 208

Group type: EXPERIMENTAL
Intervention: Classification based on methylation status (U methylated, C unmethylated)
Number of subjects: 208

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 208
Study: 27500487

Group type: EXPERIMENTAL
Intervention: Experimental protective underwear
Number of subjects: 122

Group type: COMPARATOR
Intervention: Marketed reference protective underwear
Number of subjects: 122
Study: 25439510

Group type: EXPERIMENTAL
Intervention: TENS application
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: LMT application
Number of subjects: 20
Study: 22581292

Group type: COMPARATOR
Intervention: 2×/week balance and tone group (BT)
Number of subjects: 147

Group type: EXPERIMENTAL
Intervention: 1×/week resistance training (RT1)
Number of subjects: 147

Group type: EXPERIMENTAL
Intervention: 2×/week resistance training (RT2)
Number of subjects: 147
Study: 21745726

Group type: EXPERIMENTAL
Intervention: Anodal transcranial direct current stimulation (tDCS) to the left dorsolateral prefrontal cortex, administered for 20 min at an intensity of 2.0 mA during 150 trials of a probabilistic association learning test.
Number of subjects: 20

Group type: COMPARATOR
Intervention: Sham tDCS (control condition).
Number of subjects: 20